imatinib
- 网络伊马替尼；格列卫；依马替尼
imatinibimatinib
伊马替尼
伊马替尼（Imatinib）是一种用于治疗费城染色体（Ber－Abl）阳性的慢性骨髓性白血病(简称CML)成人患者的急变期、加速期 …
格列卫
格列卫（Imatinib）是一种酪氨酸激酶（TK）抑制剂，被广泛用于治疗慢性粒细胞白血病、Ph（+）急性淋巴细胞白血病、血小 …
依马替尼
依托泊甙EtoposideCAS... ... Ifosfamide 异环磷酰胺 3778-73-2 Imatinib 依马替尼 220127-57-1 Irinotecan 伊立替康 136572-09-…
伊玛替尼
第一代药伊玛替尼（Imatinib）：诺华公司生产的格列卫（Glivec），印度公司仿制的veenat惠氏（Wyeth）公司的博舒替尼Bos…
对伊马替尼
抗肿瘤血管生成治疗... ... 和C-反应蛋白( C- reactive protein，CRP) 使对伊马替尼( imatinib， 2. 埃罗替尼( Tarceva，erlotinib) ...
替尼布
近年，医学研究出一种名为依麦替尼布（Imatinib） 的药物，能特别有效针对基质肿瘤，可减低手术后的复发机会或在扩散的情 …
伊马替你
# 伊马替你（Imatinib）：BCR-ABl酪氨酸激酶抑制剂，是一线治疗药物。68%的病人达到遗传性缓解# 羟基脲±白血病分离用于 …
伊妈替尼
酪氨酸激酶抑制剂如血小板衍生生长因子（PDGF）受体拮抗剂伊妈替尼（Imatinib）或者多激酶抑制剂索拉非尼（orafenib）已 …
1
When they tried Gleevec, known generically as imatinib, it had little effect on the cells.
当他们尝试着格列卫，通常被称依马替尼，它很少对细胞有作用。
2
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib.
有研究表明与伊马替尼相比，尼罗替尼是一种更强效的BCR-ABL抑制剂。
3
Consider using adjuvant imatinib for at least 3 (rather than 1) years in high-risk patients after resection of GIST.
考虑对手术切除后的GIST高危患者应用辅助伊马替尼治疗至少3年（而不是1年）。
4
Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
之前和之后在慢性粒细胞白血病病态肥胖病人的胃切除甲磺酸伊马替袖子药代动力学。
5
Drugs like imatinib and sunitinib inhibit their primary target in a nanomolar concentration.
如imatinib和sunitinib这样的药物在纳摩尔浓度就抑制它们的主要靶点。
6
Objective To explore the inhibitory mechanism of Imatinib mesylate on pulmonary fibrosis induced by bleomycin in mice.
目的探讨格列卫对小鼠肺纤维化的干预机制。
7
The next step, says Jiang is finding a drug that blocks AHI-1, which could potentially be given in combination with imatinib in the future.
江表示，下一步是找一种阻滞AHI-1的药物，这种药物可能在将来与伊马替尼联用于治疗。
8
Imatinib is currently the most popular therapy for chronic myeloid leukemia (CML).
伊马替尼是目前治疗慢性髓细胞白血病的最普遍药物。
9
Imatinib was re introduced in patients who had molecular relapse.
出现分子学复发的患者，再次应用伊马替尼。
10
But imatinib is known to cause heart problems in some people because it also switches off tyrosine kinases in the ABL family.
但伊马替尼是众所周知的导致心脏问题，在一些人，因为它还要开关小康酪氨酸激酶在abl的家庭。
11
Objective To study the treatment and its possible mechanism of imatinib-induced severe fluid retention in chromic myeloid leukemia(CML).
目的探讨应用伊马替尼（格列卫）治疗慢性粒细胞白血病发生严重水潴留的处理及其可能的发生机制。
12
OBJECTIVE To study and improve the synthesis of imatinib mesylate.
目的研究和改进甲磺酸伊马替尼的合成工艺。
13
Clinical Study of Chinese Gastrointestinal Stromal Tumors Patients Treated with Imatinib Mesylate
甲磺酸伊马替尼治疗国人胃肠间质瘤的临床研究
14
Resistance in the treatment for chronic myelogenous leukemia with imatinib and its management
伊马替尼治疗慢性粒细胞白血病的耐药与对策
15
Efficacy and safety evaluation of imatinib in the treatment of patients with chronic granulocytic leukemia in accelerated phase
伊马替尼治疗慢性粒细胞白血病加速期疗效评价
16
Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients
慢性髓性白血病患者伊马替尼治疗后ABL激酶区点突变分析
17
Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study
非清髓异基因造血干细胞移植联合伊马替尼治疗慢性粒细胞白血病的临床研究
18
Efficacy of imatinib mesylate in treatment of advanced gastrointestinal stromal tumors
甲磺酸伊马替尼治疗晚期胃肠道恶性间质瘤疗效的初步观察
19
Mechanism and strategy against Imatinib-resistant chronic myeloid leukemia
慢性粒细胞白血病伊马替尼耐药性的机制与对策
20
Clinical observation on the effects of low dosage imatinib to chronic myelogenous leukemia in blast crisis
小剂量伊马替尼治疗慢性髓细胞白血病急变期患者的临床疗效